Form 4: STERIS plc Executive Julia Madsen Reports Share Transaction

Julia Madsen, Sr. VP and GM of Life Sciences at STERIS plc, reports the withholding of 250 ordinary shares to cover tax obligations upon vesting of restricted shares on October 1, 2024.

Summary

• On October 1, 2024, Julia Madsen, Sr. VP and GM of Life Sciences at STERIS plc, had 250 ordinary shares withheld to cover tax obligations.
• These shares were withheld from the 493 restricted shares that vested on that date.
• The vested shares were valued at the NYSE closing market price on October 1, 2024, which was $235.78 per share.
• Following the transaction, Ms. Madsen beneficially owns 9,421 ordinary shares, of which 3,990 are restricted and will vest at various dates in the future.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing regarding an executive's share transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a routine disclosure related to executive compensation and is typical for publicly traded companies.

Comparison to Industry Standards

• Executive compensation practices, including the use of restricted stock units (RSUs) that vest over time, are common across publicly traded companies, including STERIS plc's competitors such as Getinge and Cantel Medical (now part of STERIS).
• The vesting schedules and tax withholding practices described in the document are generally in line with standard practices for equity compensation.
• Companies like Medtronic and Boston Scientific also utilize similar equity-based compensation plans to align executive interests with shareholder value.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it relates to executive compensation and alignment of interests.
• Employees may be interested in the details of executive compensation as it relates to overall company performance and reward structures.

Key Dates